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5-aza-2′-deoxycytidine (5-aza), an inhibitor of DNA methyltransferases (DNMTs), has
been implicated in aversive memory and the function of brain region involved
in processing emotion. However, little is known about the role of 5-aza in the
reconsolidation of opiate withdrawal memory. In the present study, using the morphine-
naloxone induced conditioned place aversion (CPA) model in rats, we injected
5-aza into agranular insular (AI), granular insular (GI), basolateral amygdala (BLA)
and central amygdala (CeA) immediately after the memory retrieval and tested the
behavioral consequences at 24 h, 7 and 14 days after retrieval test. We found
that 5-aza injection into AI disrupted the reconsolidation of morphine-associated
withdrawal memory, but 5-aza injection into GI had no impact on the reconsolidation.
Meanwhile, 5-aza injection into BLA but not CeA attenuated the withdrawal memory
trace 14 days later. However, 5-aza administration to rats, in the absence of
memory reactivation, had no effect on morphine-associated withdrawal memory.
These findings suggest that 5-aza interferes with the reconsolidation of opiate
withdrawal memory, and the roles of insular and amygdala in reconsolidation are
distinctive.
Keywords: DNA methylation, 5-aza-2′-deoxycytidine, morphine addiction, conditioned place aversion, insular,
amygdala
INTRODUCTION
The reactivation of opiate-withdrawal memories by cues or context previously associated with
withdrawal experience motivates drug-seeking behaviors and increases the risk of relapse
(Luo et al., 2013). After reactivated, the memories will undergo an unstable state that is
called reconsolidation process (Schiller et al., 2010). The disruption of reconsolidation results in a
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reduction in the motivational properties of stimuli previously
associated with aversive outcomes (Hellemans et al., 2006).
Actually, interfering with reconsolidation using pharmacological
approaches has been shown to erase the memories and prevent
relapse (Lee et al., 2006).
Insular cortex and amygdala are the key brain regions
for manipulating the drug-related memory reconsolidation
(Hellemans et al., 2006; Contreras et al., 2012). The insular
cortex is further subdivided into the agranular insular (AI)
and granular insular (GI; Cechetto and Saper, 1987). AI and
GI are heterogeneous brain regions with distinct functions
and neural connections (Moraga-Amaro and Stehberg, 2012).
Specifically, the GI receives and encodes primary aversive sensory
information (Moraga-Amaro and Stehberg, 2012). AI plays an
important role in the reconsolidation of amphetamine-related
memory (Contreras et al., 2012). Additionally, studies implicate
an indispensable role for the basolateral amygdala (BLA)
in the reconsolidation of drug-related withdrawal memories
(Hellemans et al., 2006). Our previous studies also showed
that infusion of the protein synthesis inhibitor anisomycin
(ANI) into the BLA after memory reactivation blocks morphine-
associated withdrawal memories reconsolidation (Wu et al.,
2014). With regard to the central amygdala (CeA), which is
also implicated in drug withdrawal-induced conditioned place
aversion (CPA; Watanabe et al., 2003), appears to be selectively
involved in mediating the reconsolidation of alcohol-related
memories (Barak et al., 2013). Furthermore, there are massive
reciprocal connections between the insular cortex and the
amygdala (Moraga-Amaro and Stehberg, 2012). The amygdala
projection from the insular cortex appears to be organized and
targeted all levels of the intra-amygdala connections linking
the lateral, basolateral and central nuclei, ultimately turning to
motivate behaviors (Shi and Cassell, 1998).
Although much progress has been made in understanding
the mechanism of memory reconsolidation, little is known
about the mechanism of transcriptional regulation. Emerging
evidence suggest that epigenetic mechanisms, including DNA
methylation, are essential regulators of memory formation and
maintaining (Zovkic et al., 2013). The methylation of cytosine
residues on DNA via DNA methyltransferases (DNMTs)
negatively regulates transcription (Foulks et al., 2012). Indeed,
studies from our laboratory found that DNMTs activity plays
a central role in the acquisition and consolidation of drug-
related reward memory (Han et al., 2010; Zhang et al., 2014).
Similarly, inhibiting the DNMTs impaired the consolidation of
contextual fear memories (Monsey et al., 2011). Reconsolidation,
a process similar to consolidation, also needed transcriptional
regulation, and recent studies found that DNMTs were required
for both the reconsolidation of pavlovian fear memories and the
reconsolidation-associated neural plasticity in lateral amygdala
(Maddox and Schafe, 2011; Maddox et al., 2014), which
suggested that DNMTs may also play an important role in the
reconsolidation of opiate-withdrawal memories. In the present
study, a CPA model was used to investigate region-specific
roles of DNMTs inhibitor 5-aza-2′-deoxycytidine (5-aza) in the
insular cortex and amygdala in the reconsolidation of morphine-
withdrawal memories.
MATERIALS AND METHODS
Subjects
A total of 166 adult male Sprague-Dawley rats (Vital
River Laboratory Animal Technology Co. Ltd., Beijing,
China) were used, 61 rats were excluded in Pre-C (pre-
conditioning), Post-C (post-conditioning) and misplacement
of microinjection site, and 105 rats were included in statistic
analysis. The rats (weighing 220–250 g, 6–7 weeks) were
housed individually in stainless metal mesh cages (25 cm
× 22.5 cm × 30 cm) on a 12:12 h light-dark cycle (light
on at 08:00) with controlled temperature (22–24◦C) and
humidity (40–60%). The experimental procedures followed
the National Institutes of Health Guide for Care and Use of
Laboratory Animals (Publication No. 85-23, revised 1985) and
the experimental protocol was approved by Research Ethics
Review Board of Institute of Psychology, Chinese Academy of
Sciences.
Surgery
After a week of acclimatization, rats were anesthetized with
sodium pentobarbital (75 mg/kg, i.p.) to implant stainless steel
guide cannulas (o.d. 0.6 mm, i.d. 0.35 mm, length 11.5 mm
for BLA, 11 mm for CeA, 9 mm for AI and GI) bilaterally
into AI (1.2 mm anterior to bregma, 5.0 mm lateral to the
midline and 6.6 mm ventral to the skull) and GI (1.2 mm
anterior to bregma, 5.0 mm lateral to the midline and 5.5 mm
ventral to the skull). The coordinates for the amygdala were the
following: BLA (2.8 mm posterior to bregma, 4.9 mm lateral
to the midline and 8.5 mm ventral to the skull) and CeA
(2.6 mm posterior to bregma, 4.2 mm lateral to the midline
and 7.9 mm ventral to the skull). All the coordinates were
fixed according to the Paxinos and Watson (2007). The guide
cannulas were secured with three small screws and dental
cement, and a capped stylet was inserted to prevent occlusion.
All rats were treated with penicillin to prevent infection (80,000
units) and allowed to recover for 7 days. The rats were handled
every other day to reduce handling stress at the time of
experiments.
Drugs and Microinjections
Morphine hydrochloride (5 mg/kg, Qinghai Pharmaceutical,
China) and naloxone hydrochloride (0.5 mg/kg, Sigma,Missouri,
MO, USA) were dissolved in 0.9% physiological saline and
were administered intraperitoneally at volumes of 1.0 ml/kg
body weight. The DNAmethyltransferase inhibitor 5-aza (Sigma,
St. Louis, MO, USA) was diluted in 0.8% acetate to a
concentration of 2 µg/µl (Han et al., 2010) in 0.9% sterile
saline. The vehicle group received isovolumetric 0.8% acetic acid
injections. The day before microinjections, we handled the rats
gently, repeatedly removed and inserted all the stylets to avoid
stress when microinjection. During the microinjection period,
each rat was gently held while the stylet was removed. The drug
or vehicle was delivered with a 10 µl Hamilton microsyringe and
the injection was given at the rate of 0.25 µl/min over 2 min with
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the injector cannula remaining in the guide cannula for another
2 min to prevent backflow.
Apparatus
The apparatus consisted of three-chamber polyvinyl chloride
(PVC) boxes. Two large-side chambers (35 cm× 31 cm× 40 cm)
were separated by a smaller chamber (14 cm × 31 cm × 40 cm).
The two larger chambers differed in their floor textures (bar and
grid, respectively) and provided distinct contexts that were paired
with morphine or saline injections. Three distinct chambers were
separated by manual guillotine doors.
Behavioral Procedures
To investigate the reconsolidation of morphine-associated
withdrawal memory, all rats should be established morphine-
associated withdrawal memory firstly. Here, we used an
unbiased, counterbalanced CPA model to train rats forming
withdrawal memory. The procedure consisted of three phases:
Pre-C, conditioning and Post-C. On day 1, baseline preference
was assessed by placing the rats in the center compartment of
the CPA apparatus. The rats were allowed freely access to all
compartments for 15 min. The Pre-C data showed that rats
had no preference. The rats that showed a strong preference
for either compartment (>540 s) were excluded. Thus, the
morphine-naloxone paired compartment was randomly assigned
for each rats, the other compartment was paired with saline.
On subsequent conditioning days, the rats were trained for
eight consecutive days, on days 2, 4, 6 and 8, each rat
was injected with saline 4 h after receiving saline injection
and immediately confined in its saline-paired compartment
for 45 min; on days 3, 5, 7 and 9, the rat was injected
with naloxone 4 h after receiving morphine injection to
induce enhanced withdrawal and confined to the corresponding
conditioning chambers for 45 min. The dose of morphine
and naloxone was selected based on our previous work (Wu
et al., 2014). Post-C for the expression of morphine/naloxone-
induced CPA in a drug-free state (15 min) was performed
on the day 11. The procedure of Post-C was the same as
the initial baseline preference assessment. The CPA score
was defined as the time spent in the morphine/naloxone-
paired chamber divided by the total time spent in both the
morphine/naloxone and the saline-paired chambers during CPA
testing.
Experiment Design
Experiment 1: Effect of Microinjection of 5-aza into AI
and GI on Reconsolidation of Morphine-Associated
Withdrawal Memory
Rats were allowed freely access to all compartments for 10
min as memory reactivation on the day after Post-C (Fan
et al., 2010; Xue et al., 2012), and DNA methyltransferase
inhibitors 5-aza or vehicle was microinjected into AI or GI
immediately after the memory reactivation. Four groups of rats
(37 rats) were used in the experiment. Two groups of rats
were used to determine whether 5-aza microinjected into AI
(1µg/0.5µl/side, n = 7) or GI (1µg/0.5µl/side, n = 10) impaired
the reconsolidation of morphine-associated withdrawal memory.
Another two groups of rats were injected with 0.8% acetic acid
into AI (0.5 µl/side, n = 8) or GI (0.5 µl/side, n = 12) as
vehicle control. After microinjection, the rats were sent back into
their home cages. After 24 h (Post-T1), 7 days (Post-T7) and
14 days (Post-T14), the rats were placed into the CPA apparatus
for 15 min to assess the effect of 5-aza on morphine-naloxone
induced CPA.
Experiment 2: Effect of Microinjection of 5-aza into
BLA and CeA on Reconsolidation of
Morphine-Associated Withdrawal Memory
The procedures were conducted similarly with experiment 1.
Another four groups of rats (34 rats) were used in experiment 2.
Two groups of rats received 0.8% acetic acid microinjection
into BLA (0.5 µl/side, n = 9) or CeA (0.5 µl/side, n = 9) as
vehicle control groups, the other two groups of rats received
5-aza microinjected into BLA (1 µg/0.5 µl/side, n = 9) or CeA
(1 µg/0.5 µl/side, n = 7). After 24 h (Post-T1), 7 days (Post-T7)
and 14 days (Post-T14), we used a drug-free test to assess the
effect of 5-aza on morphine-naloxone induced CPA.
Experiment 3: Effect of Microinjection of 5-aza into AI
and BLA on Morphine-Associated Withdrawal
Memory Without Exposure to Conditioning Chamber
After established morphine-associated aversive memory, rats
were microinjected 5-aza or 0.8% acetic acid in AI/BLA on
day 12 without memory reactivation. Two groups of rats (13 rats)
received 0.8% acetic acid microinjection into AI (0.5 µl/side,
n = 6) or BLA (0.5 µl/side, n = 7) as vehicle control, the other
two groups of rats (13 rats) received 5-aza microinjected into
AI (1 µg/0.5 µl/side, n = 7) or BLA (1 µg/0.5 µl/side, n = 6).
After 24 h (Post-T1), 7 days (Post-T7) and 14 days (Post-T14),
we used a drug-free test to assess the effect of 5-aza onmorphine-
naloxone induced CPA.
Experiment 4: Effect of Microinjection of 5-aza into AI
and BLA on Drug-Naive Rats
Following baseline preference test on day 1, rats received twice
intraperitoneally injection of saline 4 h apart and then were
confined to one of the larger chambers for 45 min for eight
consecutive days. Each rat was confined to one larger chamber
and the other larger chamber on alternating days. Post-C was
performed in a drug-free test (15min). Two groups of rats (8 rats)
received 5-aza microinjection into AI (1 µg/0.5 µl/side, n = 4) or
BLA (1 µg/0.5 µl/side, n = 4).We used a drug-free test to assess
the effect of 5-aza on drug- naive rats after 24 h (Post-T1).
Cannula Verification
At the end of experiments, the rats were anesthetized with
sodium pentobarbital (75 mg/kg) and transcardially perfused.
Cannula placements were assessed using Nissl staining with a
section thickness of 40 µm under light microscopy. Rats with
misplaced cannulas were excluded from statistical analysis.
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Statistical Analysis
The statistical analysis was performed using two-way repeated
measures analysis of variance (ANOVA), with CPA score as the
dependent factor. Post hoc analyses of significant effects were
performed using the Bonferroni test. The preference score was
analyzed by paired samples t-test to assess whether the rats
formed conditioned place preference after saline conditioning.
Values of p < 0.05 were considered statistical significant. All
data was expressed as mean ± SEM and analyzed with Prism 5
Software.
RESULTS
Cannula Verification
Placements of infusion needle tips targeted at AI, GI, BLA and
CeA were examined by postmortem histological verification.
Twenty-three rats were removed because their placements were
outside the scopes. Schematic illustrations and representative
photomicrographs of the intracranial cannula infusion sites were
presented in Figure 1.
Microinjection of 5-aza into the AI Disrupted
Reconsolidation of Morphine-Associated CPA
As shown in Figure 2, with treatment (5-aza or 0.8% acetic acid)
as the between-subjects factor and test point (Pre-C and Post-C)
as the within-subjects factor, ANOVA revealed a significant main
effect of test point (F(1,13) = 44.37, p < 0.001), indicating that
the rats in AI groups acquired CPA. Moreover, there was no
significant main effect of treatment (F(1,13) = 0.01, p > 0.05),
suggesting that no group differences before 5-aza administration.
To examine the effects of 5-aza on the reconsolidation of
morphine-withdrawal memories, the rats received 5-aza or
0.8% acetic acid microinjection into the AI immediately after
the retrieval test on the day after Post-C. The two-way
repeated measures ANOVA conducted on CPA scores, with
treatment (5-aza or 0.8% acetic acid) as the between-subjects
factor and test point (Post-C, Post-T1, Post-T7 and Post-
T14) as the within-subjects factor. ANOVA revealed significant
effects of treatment (F(1,13) = 4.70, p < 0.05) and test point
(F(3,39) = 5.56, p < 0.05) and treatment × test point interaction
(F(3,39) = 3.65, p < 0.05) in the AI. The post hoc analyses
confirmed that CPA scores significantly decreased in the group
of rats that received 5-aza infusion into the AI (p < 0.05;
Figure 2B). Moreover, as depicted in Figure 2D, 5-aza injection
into AI had no effect on the locomotor activity of rats
(p> 0.05).
In GI groups, two-way ANOVA was performed with
treatment (5-aza or 0.8% acetic acid) as the between-subjects
factor and test point (Pre-C and Post-C) as the within-subjects
factor. ANOVA revealed a significant main effect of test point
(F(1,20) = 125.70, p < 0.001), indicating that the rats in GI
groups acquired CPA. Moreover, there was no significant main
FIGURE 1 | Schematic illustrations and representative photomicrographs of the intracranial cannula infusion sites in the agranular insular (AI; A),
granular insular (GI; B), basolateral amygdala (BLA; C) and central amygdala (CeA; D). Numbers besides the sections indicate anteroposterior distance from
bregma in millimeters. Data are reconstructed from Paxinos and Watson (2007).
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FIGURE 2 | Effects of microinjection of 5-aza-2′-deoxycytidine (5-aza) into AI and GI on the reconsolidation of conditioned place aversion (CPA).
(A) Timeline of experimental procedure (B) 5-aza injection into AI blocked the reconsolidation of CPA. (C) Injection of 5-aza into GI did not disrupt the reconsolidation
of CPA. (D,E) The locomotor activity of all groups in experiment 1. Data are presented as mean ± SEM. ∗p < 0.05, compared to control at the same time point.
effect of treatment (F(1,20) = 1.25, p > 0.05), suggesting that
no group differences before 5-aza administration. The effect
of 5-aza on reconsolidation of CPA in GI was summarized
in Figure 2C. With treatment (5-aza or 0.8% acetic acid)
as the between-subjects factor and test point (Post-C, Post-
T1, Post-T7 and Post-T14) as the within-subjects factor, the
ANOVA revealed no significant main effect of treatment or
treatment × test point interaction in the GI (p > 0.1). As
depicted in Figure 2E, 5-aza injection into GI had no effect
on the locomotor activity of rats (p > 0.05). The results
suggested that blocking DNMTs in AI but not GI with 5-aza
after memory reactivation disrupted the reconsolidation of
established CPA.
Microinjection of 5-aza into BLA Attenuated
Retention of Morphine-Associated CPA
As shown in Figure 3, two-way ANOVA was conducted with
treatment (5-aza or 0.8% acetic acid) as the between-subjects
factor and test point (Pre-C and Post-C) as the within-subjects
factor. ANOVA revealed a significant main effect of test point
(F(1,16) = 47.82, p < 0.001), indicating that the rats in BLA
groups acquired CPA. Further, there was no significant effect
of treatment (F(1,16) = 1.24, p > 0.05) suggesting that no
group differences before 5-aza administration. Then 5-aza was
administered into the BLA and reconsolidation of CPA was
evaluated as described in ‘‘Materials and Methods’’ in Section.
The two-way repeated measures ANOVA, with treatment (5-aza
or 0.8% acetic acid) as the between-subjects factor and test
point (Post-C, Post-T1, Post-T7 and Post-T14) as the within-
subjects factor, showed significant effect of treatment × test
point interaction (F(3,48) = 3.73, p < 0.05). The post hoc
analyses confirmed that CPA scores significantly decreased at
Post-T14 (p < 0.05, compared to control) in the group of
rats that received 5-aza infusion (Figure 3B). These results
indicated that the effect of 5-aza injection into the BLA
on withdrawal memory reconsolidation might be extremely
weak.
In CeA groups, the two-way ANOVA was conducted with
treatment (5-aza or 0.8% acetic acid) as the between-subjects
factor and test point (Pre-C and Post-C) as the within-subjects
factor. ANOVA revealed a significant effect of test point
(F(1,14) = 60.27, p < 0.001), indicating that the rats in BLA
groups acquired CPA. Moreover, there was no significant effect
of treatment (F(1,14) = 0.26, p > 0.05), suggesting that no group
differences before 5-aza administration. The effect of 5-aza on
reconsolidation of CPA in CeA was summarized in Figure 3C.
The two-way repeated measures ANOVA, with treatment (5-aza
or 0.8% acetic acid) as the between-subjects factor and test
point (Post-C, Post-T1, Post-T7 and Post-T14) as the within-
subjects factor, revealed no significant effect of treatment or
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FIGURE 3 | Effects of microinjection of 5-aza into BLA and CeA on the reconsolidation of CPA. (A) Timeline of experimental procedure (B) 5-aza injection
into BLA attenuated the reconsolidation of CPA. (C) Injection of 5-aza into CeA did not disrupt the reconsolidation of CPA. (D,E) The locomotor activity of all groups
in experiment 2. Data are presented as mean ± SEM. ∗p < 0.05, compared to control at the same time point.
treatment × test point interaction in the CeA (p > 0.1). As
depicted in Figures 3D,E, the ANOVA demonstrated that there
was no significant main effect of ‘‘5-aza treatment’’ on the
locomotor activity in BLA groups (p > 0.05) or CeA groups
(p> 0.05).
Microinjection of 5-aza into AI and BLA Without
Memory Reactivation had no Effect on
Morphine-Associated CPA
As shown in Figure 4, two-way ANOVA was conducted
respectively in AI groups and in BLA groups with treatment
(5-aza or 0.8% acetic acid) as the between-subjects factor and test
point (Pre-C and Post-C) as the within-subjects factor. ANOVA
revealed that significant main effect of test point in AI groups
(F(1,11) = 21.45, p < 0.001) and in BLA groups (F(1,11) = 94.55,
p < 0.001), indicating that all groups acquired CPA. There were
no significant main effect of treatment in AI (F(1,11) = 0.01,
p> 0.05) or BLA (F(1,11) = 0.01, p> 0.05) groups, suggesting that
no group differences before 5-aza administration. To examine
the effect of 5-aza injection without memory reactivation on
morphine-withdrawal memories, the rats received 5-aza or 0.8%
acetic acid microinjection into the AI or BLA on the day after
Post-C (day 12). The two-way repeated measures ANOVA was
conducted on CPA scores, with treatment (5-aza or 0.8% acetic
acid) as the between-subjects factor and test point (Post-C, Post-
T1, Post-T7 and Post-T14) as the within-subjects factor. ANOVA
showed no significant main effect of treatment (F(1,11) = 0.67,
p > 0.05) or test point × treatment interaction in BLA groups
(F(3,33) = 1.77, p> 0.05). Similarly, there was no significant main
effect of treatment (F(1,11) = 0.003, p > 0.05) or test point ×
treatment interaction in AI groups (F(3,33) = 0.33, p > 0.05).
These results suggested that blocking DNMTs in AI or BLA with
5-aza without memory reactivation had no effect on established
CPA.
Microinjection of 5-aza into AI and BLA had no Effect
on Drug-naïve Rats
As shown in Figure 5, paired samples t-test showed that there
was no significant difference between Pre-C and Post-C in AI
group (t(3) = 2.93, p = 0.60) or BLA group (t(3) = 1.08, p = 0.36),
indicating that the rats failed to acquire conditioned place
preference after saline training. Then 5-aza was administered
into the AI or BLA after 10 min test, and paired samples t-test
showed no significant effect between Post-C and Post-T1 in AI
group (t(3) = 0.23, p = 0.83) or BLA group (t(3) = 0.15, p = 0.89).
These results suggested that microinjection of 5-aza into the AI
or BLA had no effect on the preference/aversion of drug-naive
rats.
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FIGURE 4 | Effects of microinjection of 5-aza into AI and BLA on morphine-withdrawal memories without exposure to conditioning chamber.
(A) Timeline of experimental procedure (B) 5-aza injection into AI without memory reactivation had no effect on CPA. (C) Injection of 5-aza into BLA without memory
retrieval had no effect on CPA. Data are presented as mean ± SEM.
DISCUSSION
In the present study, we investigated region-specific effects of
DNMTs inhibition in the insular cortex and amygdala on the
reconsolidation of morphine-withdrawal memory. We showed
that microinjection of 5-aza into the AI, but not GI, disrupted
the reconsolidation of morphine-withdrawal memory, and this
effect lasted for least 2 weeks. Inhibition of DNMTs activity
in the BLA but not CeA, weakened the established CPA at
14 days after retrieval test. Additionally, these effects of DNMTs
inhibition required that the memories be actively retrieved.
Lastly, our results showed that 5-aza had no effect on locomotor
activity and did not induce a preference or aversion on its
own. These results suggest that DNA methylation in the AI and
BLA are required for the reconsolidation of opiate-withdrawal
memory.
The amygdala and insular cortex, especially the BLA and
AI, are important components of neural circuits underlying
drug-related memory reconsolidation (Hellemans et al., 2006;
Contreras et al., 2012). Studies positively proposed that the BLA
is a critical brain region for reconsolidation and storage of CS-
withdrawal associations (Gale et al., 2004; Agren et al., 2012).
Some researches revealed that N-Methyl-D-aspartate (NMDA)
Receptors, Zif268, protein kinase Mζ (PKMζ), cyclin-dependent
kinase 5 (Cdk5), and transcription factor NF-κB in the BLA
serve to stabilizememory reconsolidation (Hellemans et al., 2006;
Milton et al., 2008; Li et al., 2010; He et al., 2011; Si et al.,
2012). The molecular mechanism of reconsolidation in the AI
remains unknown. Our results showed that microinjection of
5-aza into the AI disrupted the reconsolidation of morphine-
withdrawal memory, while microinjection of 5-aza into the
BLA weakened the subsequent CPA expression. These findings
suggested that DNMTs activity in the BLA and AI are involved
but play distinct roles in the reconsolidation of opiate-withdrawal
memories. Moreover, we found that microinjection of 5-aza
into the GI and CeA did not affect the reconsolidation.
In combination with previous findings, the GI seem to
be the key sub-regions to receive and encode primary aversive
information (Allen et al., 1991), but not involved in aversive
memory reconsolidation. Nevertheless, the reconsolidation of
morphine-associated aversive memory in the CeA might not
underlie DNAmethylation modification. In addition, our results
showed that the memory impairment induced by DNMTs
inhibition in the AI and BLA was dependent on memory
recall, because the memory impairment was not observed
when DNMTs inhibition occurred in the absence of memory
retrieval. The necessity of DNMTs inhibition for reconsolidation
might be specific to the withdrawal memories, because 5-aza
could not induce preference or aversion for saline conditioned
rats. Collectively, our findings suggested that the DNMTs
activity in the AI and BLA are critical for the reconsolidation
process.
Accumulated evidence demonstrated that DNA methylation
played an important role in the reconsolidation of fear
memories (Maddox and Schafe, 2011; Maddox et al., 2014).
The highly expression of three subtypes of DNMTs (DNMT1,
DNMT3a, DNMT3b) in adulthood (Anier et al., 2010; LaPlant
et al., 2010) suggested that dynamic regulation of DNA
methylation might be critical for neuronal function, including
synaptic plasticity and memory modulation. Studies showed
that DNMTs activity in the LA is critical not only for the
reconsolidation of fear memory (Maddox and Schafe, 2011),
but also for the reconsolidation-associated neural plasticity
(Maddox et al., 2014). In the present study, we found blockade
of DNMTs activity in the AI and BLA interfered with the
reconsolidation of morphine-associated aversive memory in
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FIGURE 5 | Effects of microinjection of 5-aza into AI and BLA on
drug-free rats. (A) Timeline of experimental procedure (B) 5-aza injection
into AI had no effect on CPA. (C) Injection of 5-aza into BLA had no effect on
CPA. Data are presented as mean ± SEM.
different manners. Our findings broaden the scope of research
on DNA methylation, particularly in reconsolidation of opiate-
withdrawal memories.
How DNA methylation modulates the reconsolidation of
withdrawal memory? We presumed that DNMTs transiently
increase the DNA methylation of downstream target genes,
which ultimately influences the reconsolidation. The DNMTs
inhibition is involved in promoting expression of memory
suppressing genes, such as protein phosphatase 1 (PP1), which
is an important molecule in the consolidation of fear memory
(Miller and Sweatt, 2007) and addiction memory (Zhang et al.,
2014). Meanwhile, PP1 is regulated by DNA methylation (Anier
et al., 2010). Thus, our results suggested that DNMTs inhibition
in the AI and BLA impaired reconsolidation of morphine-
withdrawal memory, which might act through promoting the
expression of memory suppressor genes. Another explanation
would be the interaction between DNA methylation and
histone acetylation. Several researches have indicate that DNA
methylation and histone acetylation work in concert to regulate
memory (Miller et al., 2008; Maddox and Schafe, 2011). Effects
of DNMTs inhibition on the fear memory reconsolidation
could be reversed by an histone deacetylase (HDAC) inhibitor
(Maddox and Schafe, 2011). It seems likely that HDAC inhibitor
overcomes the memory deficit produced by 5-aza by increasing
the transcriptional activity of memory promoter genes, whose
transcription is upregulated by HDAC inhibition (Vecsey
et al., 2007). These genes may then overcome the memory
suppressing effects of genes that were made aberrantly active by
the DNMT inhibition, ultimately resulting in normal memory
formation. Therefore, DNMTs inhibition might impair the
reconsolidation of withdrawal memory via regulation of histone
acetylation in the AI and BLA. Collectively, the DNAmethylation
mechanism underlying the reconsolidation of aversive memory
is complex, and a series of studies are needed to be done in the
future.
We also found distinctive effects of microinjection of 5-aza
into the AI and BLA on the reconsolidation of morphine-
withdrawal memory. Microinjection of 5-aza into the BLA
resulted in the instability of morphine-withdrawal memories,
which could not maintain 14 days after microinjection of
5-aza, whereas microinjection of 5-aza into the AI disrupted
the reconsolidation so that memory could not maintain 24 h
thereafter. One explanation for the distinctive effects is that
DNA methylation in the AI and BLA occurs at different
points of time during the reconsolidation process. Evidence
described the time-dependent reorganization of brain circuitry
underlying long-termmemory storage. For example, the changes
of metabolic activities in the hippocampus is prior to that in the
neocortex in retention of a spatial discrimination task (Bontempi
et al., 1999). This raised the intriguing idea that the points
of time when DNA methylation happens in the AI and BLA
are varied. Based on our findings, the DNA methylation in
the AI might be upregulated immediately after the memories
retrieval, while the DNA methylation upregulation in the BLA
might be delayed. Thus, one possibility of our results is that
5-aza took effect immediately after memory retrieval in AI,
and strongly inhibited DNA methylation process. Whereas,
most of 5-aza might be metabolized in the BLA when the
DNA methylation upregulated, resulting in low dose of 5-aza
and its weak effect on withdrawal memory reconsolidation.
Similar results also showed that relatively low dose of protein
synthesis inhibitors have no effect on the reconsolidation or
just weaken the process (Yu et al., 2013). Another explanation
would be that microinjection of 5-aza into the AI might
impair the reconsolidation, whereas memory deficits in BLA
could be a result of enhanced extinction learning. Obviously,
additional experiments are required to further confirm the above
hypothesis.
The present findings, for the first time, showed the
pharmacological evidence that 5-aza contributes to the
reconsolidation of conditioned opiate-withdrawal memory.
We also found the distinctive effects of 5-aza injection into the
AI and BLA on the reconsolidation of opiate-associated aversive
memory.
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